Top

Published in:

01-08-2018 | Original Research Article

Cost-Effectiveness Analysis of a Physician-Implemented Medication Screening Tool in Older Hospitalised Patients in Ireland

Authors: Gary L. O’Brien, Denis O’Mahony, Paddy Gillespie, Mark Mulcahy, Valerie Walshe, Marie N. O’Connor, David O’Sullivan, James Gallagher, Stephen Byrne

Published in: Drugs & Aging | Issue 8/2018

Abstract

Background

A recent randomised controlled trial conducted in an Irish University teaching hospital that evaluated a physician-implemented medication screening tool, demonstrated positive outcomes in terms of a reduction in incident adverse drug reactions.

Objective

The present study objective was to evaluate the cost effectiveness of physicians applying this screening tool to older hospitalised patients compared with usual hospital care in the context of the earlier randomised controlled trial.

Method

We used a cost-effectiveness analysis alongside a conventional outcome analysis in a cluster randomised controlled trial. Patients in the intervention arm (n = 360) received a multifactorial intervention consisting of medicines reconciliation, communication with patients’ senior medical team, and generation of a pharmaceutical care plan in addition to usual medical and pharmaceutical care. Control arm patients (n = 372) received usual medical and pharmaceutical care only. Incremental cost effectiveness was examined in terms of costs to the healthcare system and an outcome measure of adverse drug reactions during inpatient hospital stay. Uncertainty in the analysis was explored using a cost-effectiveness acceptability curve.

Results

On average, the intervention arm was more costly but was also more effective. Compared with usual care (control), the intervention was associated with a non-statistically significant increase of €877 (95% confidence interval − €1807, €3561) in the mean healthcare cost, and a statistically significant decrease of − 0.164 (95% confidence interval − 0.257, − 0.070) in the mean number of adverse drug reaction events per patient. The associated incremental cost-effectiveness ratio per adverse drug reaction averted was €5358. The probability of the intervention being cost effective at threshold values of €0, €5000 and €10,000 was 0.236, 0.455 and 0.680, respectively.

Conclusion

Based on the evidence presented, this physician-led intervention is not likely to be cost effective compared with usual hospital care. To inform future healthcare policy decisions in this field, more economic analyses of structured medication reviews by other healthcare professionals and by computerised clinical decision support software need to be conducted.

Available only for authorised users

Organisation for Economic Co-operation and Development. Life expectancy at birth (indicator). 2018. https://data.oecd.org/healthstat/life-expectancy-at-birth.htm. Accessed 26 Jan 2018.

Lehnert T, Heider D, Leicht H, Heinrich S, Corrieri S, Luppa M, et al. Health care utilization and costs of elderly persons with multiple chronic conditions. Med Care Res Rev. 2011;68(4):387–420.CrossRefPubMed

O’Connor MN, Gallagher P, O’Mahony D. Inappropriate prescribing. Drugs Aging. 2012;29(6):437–52.CrossRefPubMed

Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivelä S-L, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol. 2002;55(8):809–17.CrossRefPubMed

Hanlon JT, Pieper CF, Hajjar ER, Sloane RJ, Lindblad CI, Ruby CM, et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci. 2006;61(5):511–5.CrossRefPubMed

Nguyen JK, Fouts MM, Kotabe SE, Lo E. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006;4(1):36–41.CrossRefPubMed

Scott I, Jayathissa S. Quality of drug prescribing in older patients: is there a problem and can we improve it? Intern Med J. 2010;40(1):7–18.CrossRefPubMed

Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4(2):e4439.CrossRefPubMedPubMedCentral

Davies EC, Green CF, Mottram DR, Pirmohamed M. Adverse drug reactions in hospitals: a narrative review. Curr Drug Saf. 2007;2(1):79–87.CrossRefPubMed

10.

Forget EL, Roos LL, Deber RB, Walld R. Variations in lifetime healthcare costs across a population. Healthc Policy. 2008;4(1):e148–67.PubMedPubMedCentral

11.

Scott MG, Scullin C, Hogg A, et al. Integrated medicines management to medicines optimisation in Northern Ireland (2000–2014): a review. Eur J Hosp Pharm. 2015. https://doi.org/10.1136/ejhpharm-2014-000512.CrossRef

12.

Ahern F, Sahm LJ, Lynch D, McCarthy S. Determining the frequency and preventability of adverse drug reaction-related admissions to an Irish University Hospital: a cross-sectional study. Emerg Med J. 2014;31(1):24–9.CrossRefPubMed

13.

Christensen M, Lundh A. Medication review in hospitalised patients to reduce morbidity and mortality. Cochrane Database Syst Rev. 2013;(2):CD008986.

14.

Blenkinsopp A, Bond C, Raynor DK. Medication reviews. Br J Clin Pharmacol. 2012;74(4):573–80. https://doi.org/10.1111/j.1365-2125.2012.04331.x.CrossRefPubMedPubMedCentral

15.

Gillespie U, Alassaad A, Henrohn D, Garmo H, Hammarlund-Udenaes M, Toss H, et al. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med. 2009;169(9):894–900.CrossRefPubMed

16.

Hellström LM, Bondesson Å, Höglund P, Midlöv P, Holmdahl L, Rickhag E, et al. Impact of the Lund Integrated Medicines Management (LIMM) model on medication appropriateness and drug-related hospital revisits. Eur J Clin Pharmacol. 2011;67(7):741–52.CrossRefPubMed

17.

Trivalle C, Cartier T, Verny C, Mathieu AM, Davrinche P, Agostini H, et al. Identifying and preventing adverse drug events in elderly hospitalised patients: a randomised trial of a program to reduce adverse drug effects. J Nutr Health Aging. 2010;14(1):57–61.CrossRefPubMed

18.

Schmader KE, Hanlon JT, Pieper CF, Sloane R, Ruby CM, Twersky J, et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am J Med. 2004;116(6):394–401.CrossRefPubMed

19.

O’Connor MN, O’Sullivan D, Gallagher PF, Eustace J, Byrne S, O’Mahony D. Prevention of hospital-acquired adverse drug reactions in older people using Screening Tool of Older Persons’ Prescriptions and Screening Tool to Alert to Right Treatment criteria: a cluster randomized controlled trial. J Am Geriatr Soc. 2016;64(8):1558–66.CrossRefPubMed

20.

O’Sullivan D, O’Mahony D, O’Connor MN, Gallagher P, Gallagher J, Cullinan S, et al. Prevention of adverse drug reactions in hospitalised older patients using a software-supported structured pharmacist intervention: a cluster randomised controlled trial. Drugs Aging. 2016;33(1):63–73.CrossRefPubMed

21.

Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment): consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.CrossRefPubMed

22.

Hill-Taylor B, Sketris I, Hayden J, Byrne S, O’Sullivan D, Christie R. Application of the STOPP/START criteria: a systematic review of the prevalence of potentially inappropriate prescribing in older adults, and evidence of clinical, humanistic and economic impact. J Clin Pharm Ther. 2013;38(5):360–72.CrossRefPubMed

23.

Gallagher J, O’Sullivan D, McCarthy S, Gillespie P, Woods N, O’Mahony D, et al. Structured pharmacist review of medication in older hospitalised patients: a cost-effectiveness analysis. Drugs Aging. 2016;33(4):285–94.CrossRefPubMed

24.

Prevention of Adverse Drug Events (ADEs) in hospitalised older patients. https://ClinicalTrials.gov/show/NCT01467050. Accessed 21 Jun 2018.

25.

Sikdar KC, Dowden J, Alaghehbandan R, MacDonald D, Wang PP, Gadag V. Adverse drug reactions in elderly hospitalized patients: a 12-year population-based retrospective cohort study. Ann Pharmacother. 2012;46(7–8):960–71.CrossRefPubMed

26.

Economic and Social Research Institute (ESRI) Activity in acute public hospitals in Ireland. Annual report 2012. Ireland. 2013. http://www.hpo.ie/latest_hipe_nprs_reports/HIPE_2012/HIPE_Report_2012.pdf. Accessed 05 Jan 2018.

27.

Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661.CrossRefPubMed

28.

Health Information and Quality Authority (HIQA). Guidelines for the economic evaluation of health technologies in Ireland. Ireland. 2017. https://www.hiqa.ie/sites/default/files/2017-10/Draft_HIQA_Economic_Guidelines_2017_consultation.pdf. Accessed 6 Jan 2018.

29.

Health Service Executive (HSE). Consolidated salary scales in accordance with Financial Emergency Measures in the Public Interest Act 2013. Ireland. 2013. http://www.hse.ie/eng/staff/benefitsservices/pay/July%202013.pdf. Accessed 4 Jan 2018.

30.

Gallagher PF, O’Connor MN, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011;89(6):845–54.CrossRefPubMed

31.

Healthcare Pricing Office (HPO). Hospital in-patient enquiry scheme (HIPE) report 2012. Dublin: Department of Health (DoH); 2012.

32.

Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015.

33.

Gyllensten H, Jönsson AK, Hakkarainen KM, Svensson S, Hägg S, Rehnberg C. Comparing methods for estimating direct costs of adverse drug events. Value Health. 2017;20(10):1299–310.CrossRefPubMed

34.

Gomes M, Ng ESW, Grieve R, Nixon R, Carpenter J, Thompson SG. Developing appropriate methods for cost-effectiveness analysis of cluster randomized trials. Med Decis Mak. 2012;32(2):350–61.CrossRef

35.

Gillespie P, O’Shea E, Casey D, Murphy K, Devane D, Cooney A, et al. The cost-effectiveness of a structured education pulmonary rehabilitation programme for chronic obstructive pulmonary disease in primary care: the PRINCE cluster randomised trial. BMJ Open. 2013;3(11):e003479.CrossRefPubMedPubMedCentral

36.

Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry. 2005;187:106–8.CrossRefPubMed

37.

Hoch JS, Rockx MA, Krahn AD. Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of “community acquired” syncope. BMC Health Serv Res. 2006;6(1):68.CrossRefPubMedPubMedCentral

38.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Cost Eff Resour Alloc. 2013;11(1):6.CrossRefPubMedPubMedCentral

39.

Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005;8(5):521–33.CrossRefPubMed

40.

Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8(1):18.CrossRefPubMedPubMedCentral

41.

Rottenkolber D, Schmiedl S, Rottenkolber M, Farker K, Saljé K, Mueller S, et al. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf. 2011;20(6):626–34.CrossRefPubMed

42.

Godfrey C, Heather N, Bowie A, Brodie J, Parrott S, Ashton H, et al. Randomised controlled trial of two brief interventions against long-term benzodiazepine use: cost-effectiveness. Addict Res Theory. 2008;16(4):309–17.CrossRef

43.

Campbell F, Karnon J, Czoski-Murray C, Jones R. A systematic review of the effectiveness and cost-effectiveness of interventions aimed at preventing medication error (medicines reconciliation) at hospital admission. Report for the National Institute for Health and Clinical Excellence as part of the Patient Safety Pilot. Sheffield: The University of Sheffield, School of Health and Related Research; 2007.

44.

Gallagher J, McCarthy S, Byrne S. Economic evaluations of clinical pharmacist interventions on hospital inpatients: a systematic review of recent literature. Int J Clin Pharm. 2014;36(6):1101–14.CrossRefPubMed

45.

Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons. https://ClinicalTrials.gov/show/NCT02097654. Accessed 21 Jun 2018.

46.

OPtimising thERapy to Prevent Avoidable Hospital Admissions in the Multimorbid Older People. https://ClinicalTrials.gov/show/NCT02986425. Accessed 21 Jun 2018.

47.

Dalton K, O’Brien G, O’Mahony D, Byrne S. Computerised interventions designed to reduce potentially inappropriate prescribing in hospitalised older adults: a systematic review and meta-analysis. Age Ageing. 2018. https://doi.org/10.1093/ageing/afy086. Epub ahead of print.

48.

Kuperman GJ, Gibson RF. Computer physician order entry: benefits, costs, and issues. Ann Intern Med. 2003;139(1):31.CrossRefPubMed

49.

Tierney WM, Miller ME, Overhage JM, McDonald CJ. Physician inpatient order writing on microcomputer workstations: effects on resource utilization. JAMA. 1993;269(3):379–83.CrossRefPubMed

50.

Regier DA, Sunderji R, Lynd LD, Gin K, Marra CA. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. CMAJ. 2006;174(13):1847–52.CrossRefPubMedPubMedCentral

51.

Ghatnekar O, Bondesson Å, Persson U, Eriksson T. Health economic evaluation of the Lund Integrated Medicines Management Model (LIMM) in elderly patients admitted to hospital. BMJ Open. 2013;3(1):e001563.CrossRefPubMedPubMedCentral

52.

O’Sullivan D, O’Mahony D, O’Connor MN, Gallagher P, Cullinan S, O’Sullivan R, et al. The impact of a structured pharmacist intervention on the appropriateness of prescribing in older hospitalized patients. Drugs Aging. 2014;31(6):471–81.CrossRefPubMed

53.

Zermansky AG, Silcock J. Is medication review by primary-care pharmacists for older people cost effective? Pharmacoeconomics. 2009;27(1):11–24.CrossRefPubMed

54.

Buck MD, Atreja A, Brunker CP, Jain A, Suh TT, Palmer RM, et al. Potentially inappropriate medication prescribing in outpatient practices: prevalence and patient characteristics based on electronic health records. Ame J Geriatr Pharmacother. 2009;7(2):84–92.CrossRef

55.

Bierman AS, Pugh MJV, Dhalla I, Amuan M, Fincke BG, Rosen A, et al. Sex differences in inappropriate prescribing among elderly veterans. Am J Geriatr Pharmacother. 2007;5(2):147–61.CrossRefPubMed

56.

Hofer-Dueckelmann C, Prinz E, Beindl W, Szymanski J, Fellhofer G, Pichler M, et al. Adverse drug reactions (ADRs) associated with hospital admissions: elderly female patients are at highest risk. Int J Clin Pharmacol Ther. 2011;49(10):577.CrossRefPubMed

57.

Patterson SM, Hughes CM, Cardwell C, Lapane KL, Murray AM, Crealey GE. A cluster randomized controlled trial of an adapted US model of pharmaceutical care for nursing home residents in Northern Ireland (Fleetwood Northern Ireland study): a cost-effectiveness analysis. J Am Geriatr Soc. 2011;59(4):586–93.CrossRefPubMed

58.

McHorney CA. Measuring and monitoring general health status in elderly persons: practical and methodological issues in using the SF-36 Health Survey. Gerontologist. 1996;36(5):571–83.CrossRefPubMed

59.

Panageas KS, Schrag D, Russell Localio A, Venkatraman ES, Begg CB. Properties of analysis methods that account for clustering in volume—outcome studies when the primary predictor is cluster size. Stat Med. 2007;26(9):2017–35.CrossRefPubMed

60.

Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001;38(6):666–71. https://doi.org/10.1067/mem.2001.119456.CrossRefPubMed

61.

Gallagher J, Byrne S, Woods N, Lynch D, McCarthy S. Cost-outcome description of clinical pharmacist interventions in a university teaching hospital. BMC Health Serv Res. 2014;14(1):177.CrossRefPubMedPubMedCentral

62.

Yagudina RI, Kulikov AU, Serpik VG, Ugrekhelidze DT. Concept of combining cost-effectiveness analysis and budget impact analysis in health care decision-making. Value Health Reg Issues. 2017;13:61–6.CrossRefPubMed

63.

Lam MPS, Cheung BMY. The use of STOPP/START criteria as a screening tool for assessing the appropriateness of medications in the elderly population. Expert Rev Clin Pharmacol. 2012;5(2):187–97.CrossRefPubMed

Title: Cost-Effectiveness Analysis of a Physician-Implemented Medication Screening Tool in Older Hospitalised Patients in Ireland
Authors: Gary L. O’Brien
Denis O’Mahony
Paddy Gillespie
Mark Mulcahy
Valerie Walshe
Marie N. O’Connor
David O’Sullivan
James Gallagher
Stephen Byrne
Publication date: 01-08-2018
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 8/2018
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-018-0564-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Objective

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2018

How Common is Statin Use in the Oldest Old?

Safety of Antidepressant Classes Used Following Traumatic Brain Injury Among Medicare Beneficiaries: A Retrospective Cohort Study

Treatment of Glioblastoma in the Elderly

Kidney Function, Polypharmacy, and Potentially Inappropriate Medication Use in a Community-Based Cohort of Older Adults

Pharmacokinetic Factors to Consider in the Selection of Antiseizure Drugs for Older Patients with Epilepsy

Pharmacological Interventions to Improve Muscle Mass, Muscle Strength and Physical Performance in Older People: An Umbrella Review of Systematic Reviews and Meta-analyses

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage